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the corresponding European Society of Cardiolo‑
gy Guidelines (SCAD, 2013; UA/NSTEMI, 2015; 
STEMI, 2017). Moreover, in all groups (except for 
controls), the presence of coronary atherosclerot‑
ic plaque was confirmed by coronary angiography, 
and plaque burden was assessed by the Gensini 
score.5 Patients from STEMI and NSTEMI groups 
presented with type 1 myocardial infarction.
Exclusion criteria Patients with at least one of 
the following criteria were excluded from the 
study: presence of malignant neoplastic, active 
autoimmune, or rheumatic disease; surgery or 
invasive intervention in the previous 6 months; 
estimated glomerular filtration rate (calculated 
using the Modification in Diet of Renal Disease 
formula) of less than 45 ml/min/1.73 m2; dia‑
betes mellitus; and active infection in the previ‑
ous 3 months. Additional exclusion criteria for 
the SCAD group were previous ACS and percu‑
taneous coronary intervention (PCI) with stent 
implantation.
Study population A total of 60 patients and vol‑
unteers were initially recruited to the study. All 
persons provided written informed consent for 
participation. Finally, 43 individuals were en‑
rolled: 1) ACS group (n = 25), including 8 pa‑
tients with STEMI, 9 patients with NSTEMI, 
and 8 patients with UA; 2) SCAD group (n = 8); 
and the control group (n = 8).
Introduction Stable atherosclerotic plaque 
manifests clinically as stable coronary artery 
disease (SCAD), whereas unstable or vulnera‑
ble plaque—as acute coronary syndrome (ACS), 
which is further divided into unstable angina 
(UA) and myocardial infarction with and with‑
out ST ‑segment elevation (STEMI and NSTEMI, 
respectively). Rupture of a vulnerable plaque 
leads to thrombus generation, coronary artery 
occlusion, and subsequent cardiac muscle ne‑
crosis with dynamically increased serum tropo‑
nin I levels, which is clinically defined as type 1 
myocardial infarction.1 The process of plaque de‑
stabilization and cardiac necrosis is associated 
with extracellular matrix alterations, in which 
metalloproteinases, such as matrix metallopro‑
teinase 9 (MMP‑9), play a pivotal role.2 MMP‑9 
is upregulated epigenetically by microRNA‑21 
(miRNA‑21), which downregulates the expres‑
sion of MMP‑9 inhibitors—reversion ‑inducing‑
cysteine ‑rich protein with Kazal motifs and tis‑
sue inhibitor of metalloproteinase 3.3,4 We aimed 
to investigate whether miRNA‑21 expression 
is enhanced in patients with ACS (with and with‑
out cardiac necrosis), as compared with patients 
with SCAD and healthy controls.
Methods Study design and inclusion criteria 
In this pilot study, participants were catego‑
rized into the following groups: STEMI, NSTE‑
MI, UA, SCAD, and healthy controls, according to 
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younger and included mostly women, without 
active smokers. The second analysis (STEMI vs 
NSTEMI vs UA vs SCAD vs controls) revealed 
significant differences only between UA and 
STEMI groups in terms of active smoking. No 
differences in BMI and hemoglobin levels were 
shown in any of the analyses. The mean (SD) 
Gensini score was 59.1 (27.3) for STEMI, 86.8 
(39.3) for NSTEMI, 66.3 (31.0) for UA, and 65.9 
(54.5) for SCAD, without significant differenc‑
es between groups. In the entire study popula‑
tion, 3 patients presented with carotid stenosis 
(2 from the NSTEMI and 1 from the UA group), 
and 1 patient from the UA group had peripheral 
artery disease. Among patients with myocardi‑
al infarction, 2 patients with STEMI (25%) and 
6 patients with NSTEMI (66.7%) presented with 
the onset of chest pain more than 12 hours be‑
fore admission.
Differences in relative hsa ‑miR‑21‑5p expression 
between 3 study groups The hsa ‑miR‑21‑5p ex‑
pression in the ACS group showed nonnormal 
distribution. Patients from the ACS group had 
similar relative hsa ‑miR‑21‑5p expression as pa‑
tients from the SCAD group and controls (medi‑
an [IQR], 2.47  [1.46–4.68], 1.90 [1.02–3.25], and 
1.81 [0.99–2.60], respectively; P = 0.15).
Differences in relative hsa ‑miR‑21‑5p expression 
between 5 study groups and correlation with tro‑
ponin I The reciprocal analysis revealed that 
patients with STEMI had a  higher relative 
hsa ‑miR‑21‑5p expression than patients with 
UA (mean [SEM], 5.96 [1.43] vs 2.31 [0.46], P 
= 0.04) and SCAD (mean [SEM], 5.96 [1.43] vs 
2.32 [0.51], P = 0.04). The relative expression 
level did not differ between the UA and SCAD 
groups (mean [SEM], 2.31 [0.46] vs 2.32 [0.51], P 
= 0.99). The STEMI group, unlike the UA group, 
differed significantly in relative hsa ‑miR‑21‑5p 
expression levels from the control group. There 
was no difference between the SCAD and con‑
trol group (mean [SEM], 2.32 [0.51] vs 1.79 [0.35], 
P = 0.43) (FigURE 1). The hsa ‑miR‑21‑5p expression 
in the NSTEMI group showed nonnormal distri‑
bution (median [IQR], 1.49 [1.44–3.49]), and no 
significant differences were observed between 
NSTEMI and other groups. Moreover, patients 
with STEMI and NSTEMI showed a  fair, al‑
though nonsignificant, correlation between se‑
rum troponin I levels after PCI and relative hsa‑
‑miR‑21‑5p expression (rs = 0.53), with a negligi‑
ble correlation between baseline troponin I lev‑
els and hsa ‑miR‑21‑5p expression.
Discussion Darabi et al6 showed that the rela‑
tive expression level of hsa ‑miR‑21‑5p is elevat‑
ed in patients with ACS, as compared with those 
with SCAD, and correlates positively with se‑
rum MMP‑9 and high ‑sensitivity C ‑reactive pro‑
tein levels.6 However, our results demonstrated 
Blood samples Blood samples for miRNA anal‑
ysis and blood investigations (hemoglobin, lipid 
panel, creatinine) were taken within the first 24 
hours of admission before PCI. Blood samples 
in EDTA tubes were centrifuged at 1200 × g for 
10 minutes to separate plasma from blood cells. 
Then, the plasma was aliquoted into microcen‑
trifuge tubes, frozen on dry ice, and immediate‑
ly stored at –80°C. Blood troponin I levels in pa‑
tients with ACS were measured on admission and 
after at least 8 hours from admission, after PCI.
Detection of hsa ‑miR‑21‑5p The miRNA parti‑
cles measured in the plasma samples were as fol‑
lows: cel ‑miR‑39‑3p (a “spike ‑in” control), hsa‑
miR‑93‑3p, hsa ‑miR‑191‑5p (control miRNAs), 
and hsa ‑miR‑21‑5p (study miRNA). Isolation of 
miRNA and quantitative reverse transcription 
polymerase chain reaction were performed with 
the use of TaqMan Advanced miRNA Assays 
(Thermo Fisher Scientific, Waltham, Massachu‑
setts, United States), according to the manufac‑
turer’s protocol. The obtained cycle ‑of ‑threshold 
(Ct) values for study hsa ‑mir‑21‑5p, as well as 
hsa ‑mir‑191‑5p and hsa ‑mir‑93‑3p as endoge‑
nous controls, were normalized by the Ct of cel‑
‑miR‑39‑3p and were used to calculate relative 
expression using the 2‑∆∆Ct method.
Ethical approval The study was approved by 
the local Research Ethics Committee of the Med‑
ical University of Warsaw, Warsaw, Poland 
(KB/55/2016 and KB/26/A/2017).
Statistical analysis All analyses were performed 
using STATISTICA 13 (StatSoft Inc., Tulsa, Okla‑
homa, United States). Results were presented 
as mean and SD, standard error of the mean 
(SEM), or median values and interquartile rang‑
es (IQRs) according to the normality of distribu‑
tion (Shapiro–Wilk test). The t test, Cochrane–
Cox test (for nonequal variances), and the anal‑
ysis of variance F test were used for normally 
distributed continuous variables. The Kruskal–
Wallis test, Mann–Whitney test, and the Spear‑
man rank correlation coefficient (rs) were used 
for nonnormally distributed continuous vari‑
ables. Categorical variables were compared us‑
ing the χ2 test. P values of less than 0.05 were 
considered significant.
Results Baseline characteristics The groups 
were compared in terms of demographic param‑
eters (age and sex), body mass index (BMI), his‑
tory of hypertension, active smoking, and se‑
rum low‑density lipoprotein cholesterol (LDL‑
C) levels, which constitute the major risk factors 
for atherosclerosis. In the first analysis (ACS 
vs SCAD vs controls), the SCAD group showed 
lower LDL‑C levels than both the ACS and con‑
trol groups as well as less frequent active smok‑
ing than the ACS group. The control group was 
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in the infarcted zone of mouse hearts.7 In a hu‑
man study, elevated serum hsa ‑miR‑21‑5p ex‑
pression, measured 5 days after STEMI in 198 pa‑
tients, was significantly correlated with the prob‑
ability of left ventricular remodeling.8 However, 
another study demonstrated a negative corre‑
lation between hsa ‑miR‑21‑5p and both LDL‑
C and total cholesterol levels in patients with 
increased serum hsa ‑miR‑21‑5p levels in patients 
with STEMI, as compared with those with UA 
and SCAD, without differences between UA and 
SCAD groups. 
There is some evidence that hsa ‑miR‑21‑5p is 
involved in extracellular matrix regulation dur‑
ing myocardial necrosis. A study on C57BL/6 mice 
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 Figure 1 Correlations between study groups in terms of hsa ‑miR‑21‑5p relative expression level: A – patients with ST ‑segment elevation myocardial infarction 
(STEMI) and unstable angina (UA); B – STEMI and stable coronary artery disease (SCAD); C – UA and SCAD; D – STEMI and controls; E – UA and controls; and F – SCAD 
and controls. Data are presented as mean (standard error of the mean). A P value of less than 0.05 was considered significant. Significant values are marked in bold.
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non–ST ‑segment elevation ACS, which suggests 
that this miRNA might participate in the regu‑
lation of lipid homeostasis in this population.9
In conclusion, diverse physiologic and patho‑
physiologic processes within the heart (eg, dif‑
ferentiation of cardiomyoblasts to cardiomyo‑
cytes, fibrosis, hypertrophy) depend on miR‑
NA particles, which might function as “molec‑
ular switches” promoting the pathways that are 
either beneficial or detrimental.10 The overex‑
pression of certain miRNA particles might be 
associated with particular clinical situations. 
For instance, a study in 43 patients revealed 
that serum hsa ‑miR‑124 expression levels dis‑
tinguished patients with an occluded infarct‑
‑related coronary artery from those with pat‑
ent arteries (area under the receiver operating 
characteristic curve, 0.787).11 
Considering the above data, the analysis 
of miRNA particles might be a promising diag‑
nostic and therapeutic method. Therefore, these 
particles should be investigated as integral el‑
ements of complex molecular pathways in car‑
diac pathobiology.
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